189 related articles for article (PubMed ID: 34571866)
1. A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer.
Perez SM; Dimastromatteo J; Landen CN; Kelly KA
Cells; 2021 Aug; 10(9):. PubMed ID: 34571866
[TBL] [Abstract][Full Text] [Related]
2. Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin‑resistant SKOV3/DDP ovarian cancer cells.
Zhong Y; Le F; Cheng J; Luo C; Zhang X; Wu X; Xu F; Zuo Q; Tan B
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760192
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
4. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A
Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo.
Kandala PK; Srivastava SK
Drug Discov Ther; 2012 Apr; 6(2):94-101. PubMed ID: 22622019
[TBL] [Abstract][Full Text] [Related]
6. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
7. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
8. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
9. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
10. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
Kandala PK; Srivastava SK
BMC Med; 2012 Jan; 10():9. PubMed ID: 22280969
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
12. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
13. CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis.
Burgos-Ojeda D; Wu R; McLean K; Chen YC; Talpaz M; Yoon E; Cho KR; Buckanovich RJ
Mol Cancer Ther; 2015 Jul; 14(7):1717-27. PubMed ID: 25969154
[TBL] [Abstract][Full Text] [Related]
14. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
Guo Y; Nemeth J; O'Brien C; Susa M; Liu X; Zhang Z; Choy E; Mankin H; Hornicek F; Duan Z
Clin Cancer Res; 2010 Dec; 16(23):5759-69. PubMed ID: 20699329
[TBL] [Abstract][Full Text] [Related]
15. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
16. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
Yuan S; Xu Y; Yi T; Wang H
J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
[TBL] [Abstract][Full Text] [Related]
17. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
18. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
19. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
[TBL] [Abstract][Full Text] [Related]
20. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
